drugset / Trial / NCT01279915

A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects

NCT01279915

Phase 1 Completed 32 enrolled Astellas Pharma Inc
RandomizedParallel-groupTriple-blind

Summary

A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending dose of ASP0456 in non-elderly healthy subjects.

Timeline

Start
2010-10
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide Oral

Indications

No indication recorded.